|
Acton Pharmaceuticals, Inc. Announces Publication of AEROSPAN(R) (Flunisolide …
MarketWatch (press release) AEROSPAN Inhalation Aerosol is an orally inhaled corticosteroid indicated for the maintenance treatment of asthma as prophylactic therapy in adult and pediatric patients 6 years of age and older. In this double-blind, placebo-controlled study, … |
View full post on asthma – Google News